This protocol covers the management of Langerhans cell histiocytosis (LCH) with onset in childhood and adolescence — specifically, localized single-system disease presenting as a single skeletal lesion (excluding CNS-risk sites) or an isolated cutaneous lesion.
Patient age under 18 years with localized, single-system LCH confined to a solitary bone lesion (other than CNS-risk lesions) or an isolated skin lesion. Clinical evidence indicates that the majority of patients in this category do not require systemic treatment.
Management is guided by lesion characteristics, symptom burden, and anatomical location. Local and conservative measures are selected by presentation — which specific interventions apply, and in what sequence, is detailed in the full structured protocol.
This document refers to Langerhans cell histiocytosis with onset in childhood and adolescence (age < 18 years).
Patients with single skeletal lesions other than "CNS-risk lesions" usually do not need systemic treatment (except for large symptomatic lesions or lesions in weight-bearing bones, which are not easily accessible for surgical treatment).
According to existing clinical experience, the majority of patients with localized LCH (mostly confined to skeleton) do not need systemic treatment.
A "wait and see" approach is justified in small asymptomatic osseous or cutaneous lesions in view of the high likelihood for spontaneous healing.
Surgical procedures such as biopsy, curettage, or resection are used to treat solitary bone lesions, solitary affected lymph nodes, or solitary circumscribed nodular skin lesions.
An intralesional application of crystalline methylprednisolone (100-150mg) in symptomatic bone lesion can quickly bring about a reduction in symptoms and facilitated cure.
Because of its potential to induce secondary malignancies, radiotherapy at a low dose (6-10 Gy) is limited to specific indications (for example, imminent compression of vital structures (e.g. the spinal cord or the optic nerve)).
View source ↗